SARS-CoV-2 escape from a highly neutralizing COVID-19 convalescent plasma
-
- Emanuele Andreano
- Monoclonal Antibody Discovery Lab, Fondazione Toscana Life Sciences, 53100 Siena, Italy;
-
- Giulia Piccini
- VisMederi S.r.l., 53100 Siena, Italy;
-
- Danilo Licastro
- ARGO Open Lab Platform for Genome Sequencing, 34149 Trieste, Italy;
-
- Lorenzo Casalino
- Department of Chemistry and Biochemistry, University of California San Diego, La Jolla, CA 92093;
-
- Nicole V. Johnson
- Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX 78712;
-
- Ida Paciello
- Monoclonal Antibody Discovery Lab, Fondazione Toscana Life Sciences, 53100 Siena, Italy;
-
- Simeone Dal Monego
- ARGO Open Lab Platform for Genome Sequencing, 34149 Trieste, Italy;
-
- Elisa Pantano
- Monoclonal Antibody Discovery Lab, Fondazione Toscana Life Sciences, 53100 Siena, Italy;
-
- Noemi Manganaro
- Monoclonal Antibody Discovery Lab, Fondazione Toscana Life Sciences, 53100 Siena, Italy;
-
- Alessandro Manenti
- VisMederi S.r.l., 53100 Siena, Italy;
-
- Rachele Manna
- VisMederi S.r.l., 53100 Siena, Italy;
-
- Elisa Casa
- VisMederi S.r.l., 53100 Siena, Italy;
-
- Inesa Hyseni
- VisMederi S.r.l., 53100 Siena, Italy;
-
- Linda Benincasa
- VisMederi Research S.r.l., 53100 Siena, Italy;
-
- Emanuele Montomoli
- VisMederi S.r.l., 53100 Siena, Italy;
-
- Rommie E. Amaro
- Department of Chemistry and Biochemistry, University of California San Diego, La Jolla, CA 92093;
-
- Jason S. McLellan
- Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX 78712;
-
- Rino Rappuoli
- Monoclonal Antibody Discovery Lab, Fondazione Toscana Life Sciences, 53100 Siena, Italy;
抄録
<jats:title>Significance</jats:title> <jats:p>This work shows that, under strong immune pressure, SARS-CoV-2 can use mutations in both the N-terminal domain and the receptor-binding domain to escape potent polyclonal neutralizing responses. Indeed, after a long period under immune selective pressure, SARS-CoV-2 evolved to evade the immunity of a potent polyclonal serum from a COVID-19 convalescent donor. Only three mutations were sufficient to generate this escape variant. The new virus was resistant to 70% of the neutralizing antibodies tested and had a decreased susceptibility to all convalescent sera. Our data predict that, as the immunity in the population increases, following infection and vaccination, new variants will emerge, and therefore vaccines and monoclonal antibodies need to be developed to address them.</jats:p>
収録刊行物
-
- Proceedings of the National Academy of Sciences
-
Proceedings of the National Academy of Sciences 118 (36), e2103154118-, 2021-08-20
Proceedings of the National Academy of Sciences